Lantern Pharma

The AI in clinical trials market is projected to grow from $1.20 billion in 2023 to $2.74 billion by 2030, driven by a 12.4% CAGR. Factors include high clinical trial failure rates, need for drug pharmacokinetics, and toxicity management. AI aims to enhance drug approval prospects and reduce trial costs.

Lantern Pharma has dosed the first Taiwanese patient in a Phase II trial of LP-300 for never-smoker NSCLC, expanding its HARMONIC trial to Asia. Preliminary results showed an 86% clinical benefit rate and 43% objective response rate. LP-300, designed using the company's AI-driven RADR platform, aims to address a critical unmet need in this patient population.

Lantern Pharma enrolled the first patient in its Phase II HARMONIC trial in Taiwan, evaluating LP-300 for never-smoker NSCLC patients progressing after TKI treatment. The trial, also ongoing in the US, aims to enroll up to 90 patients across Taiwan, Japan, and the US, with primary endpoints of PFS and OS. Preliminary results from a lead-in cohort showed 6 out of 7 patients experienced clinical benefit from LP-300-chemotherapy combination.

Lantern Pharma enrolls first patient in Taiwan for Phase 2 HARMONIC™ trial evaluating LP-300 in never-smoker NSCLC patients, highlighting Taiwan's significance due to over 50% of lung cancer cases occurring in never-smokers.

FDA grants Fast Track Designation to LP-184 for Triple Negative Breast Cancer (TNBC), recognizing its potential to address unmet needs in aggressive cancers. LP-184 has shown significant preclinical efficacy in TNBC models, including those resistant to PARP inhibitors, and promising synergy with checkpoint inhibitors. The drug is currently in a Phase 1A clinical trial for multiple solid tumor indications.

Lantern Pharma's LP-184 receives FDA Fast Track Designation for Triple Negative Breast Cancer, following a previous designation for Glioblastoma. LP-184, developed using the RADR® AI platform, demonstrated tumor regression in TNBC models and is in Phase 1A trials for safety and tolerability in solid tumors. The drug targets TNBC, which has limited treatment options and poor prognosis.

Lantern Pharma (LTRN) specializes in precision cancer treatment using AI and ML, focusing on biomarker-based genetic screening to reduce drug development costs and time. The RADR platform accelerates precision therapy development, and the company strategically acquires or partners with other entities to advance personalized medicine. Recent achievements highlight its potential to revolutionize cancer treatment.